芳樟醇是一種單萜類的芳香油,研究顯示芳樟醇具有抗腫瘤,抗細菌,抗憂鬱,抗發炎鎮痛等作用。但芳樟醇是一種油性物質,如何讓芳樟醇被身體吸收便是本研究的目的。本次實驗希望開發經皮傳遞系統,但皮膚上層的角質層具有保護,會阻礙藥物穿透吸收,因此希望藉由劑型包覆讓芳樟醇更容易進入體內。微乳劑經由實驗設計法進行處方設計,透過物化性質評估、體外穿透試驗、刺激性試驗及製劑安定性進行篩選。結果顯示配方LL02具有良好的皮膚穿透能力,第24h皮膚穿透累積量和第24h皮膚累積量,分別為對照組的4.5倍和6.2倍。配方LL02在刺激性實驗和安定試驗中顯示,配方不具有刺激性並且能夠安定存放,具有潛力繼續進行開發。
Linalool is one kind of the monoterpene oil. In many researches, Linalool had been demonstrated that it has many aspects of the pharmacology such as antitumor, antibacterial, antidepressant, anti-inflammatory and analgesic effect. Hence, we want to develop Linalool as the drug. Transdermal system is the useful replacement method to avoid the first pass effect and invasive administration. The stratum corneum is the barrier of the skin which is the first line guardian to protect our body from the environmentally invasive things like virus, bacterial, chemical particles. Due to the skin barrier, we use the microemulsion to improve our drug permeable ability. We used the mixture design and response surface methodology to obtain the optimal formulation. The physicochemical properties study, in vitro permeation study, irritation test and stability determination of the optimal formulation were conducted. The results show that the transdermal amount and the disposition amount at the skin of optimal formulation LL02 increased 4.5 folds and 6.2 folds respectively when compared to control group. Besides, in the irritation test and the thermodynamic stability test also show that the LL02 didn’t cause the skin irritation and maintained stably. As the result of the study, the formulation of LL02 is potential to further develop.